Diabetes · Connecticut
Diabetes studies in Connecticut
28 studies have at least one recruiting site in Connecticut. Diabetes research covers type 1 and type 2 diabetes, prediabetes and related complications, testing medicines, devices such as glucose monitors and insulin pumps, and lifestyle programs.
28 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Waterbury, CT + 55 other US sites
- Eligibility basics
- Ages 18–79
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Merck Sharp & Dohme LLC
- Location
- Manchester, CT + 27 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)
Merck Sharp & Dohme LLC
- Location
- Waterford, CT + 18 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Eli Lilly and Company
- Location
- Stamford, CT + 11 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
Boehringer Ingelheim
- Location
- Bridgeport, CT + 199 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 1/Phase 2
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated
Boehringer Ingelheim
- Location
- Waterford, CT + 24 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Sanofi
- Location
- New Haven, CT + 33 other US sites
- Eligibility basics
- Ages 1–25
- RecruitingPhase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Hoffmann-La Roche
- Location
- New Haven, CT + 43 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Regeneron Pharmaceuticals
- Location
- Waterbury, CT + 20 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Regeneron Pharmaceuticals
- Location
- New Haven, CT + 55 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly and Company
- Location
- Bridgeport, CT + 59 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
Eli Lilly and Company
- Location
- Waterbury, CT + 68 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema
Novo Nordisk A/S
- Location
- Waterbury, CT + 36 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
Eli Lilly and Company
- Location
- Hamden, CT + 34 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly and Company
- Location
- Waterbury, CT + 40 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2/Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
CSL Behring
- Location
- Bloomfield, CT + 147 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
Mannkind Corporation
- Location
- New Haven, CT + 9 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Eli Lilly and Company
- Location
- New Haven, CT + 39 other US sites
- Eligibility basics
- Ages 10–17
- Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
Insulet Corporation
- Location
- New Haven, CT + 10 other US sites
- Eligibility basics
- Ages 14–75
- RecruitingPhase 3
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
Vertex Pharmaceuticals Incorporated
- Location
- Waterbury, CT + 69 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 2
A Chronic Pain Master Protocol (CPMP): A Study of LY4065967 in Participants With Diabetic Peripheral Neuropathic Pain
Eli Lilly and Company
- Location
- Hamden, CT + 35 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
Neurologic Stem Cell Treatment Study
MD Stem Cells
- Location
- Westport, CT + 1 other US site
- Eligibility basics
- Ages 18+
- RecruitingPhase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Zucara Therapeutics Inc.
- Location
- New Haven, CT + 36 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingHealthy volunteers
Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)
Yale University
- Location
- New Haven, CT
- Eligibility basics
- Ages 18–60
Who these studies look for
Studies commonly set an HbA1c range, a diagnosis duration and a list of allowed or excluded medications. Some also recruit people without diabetes as a comparison group.
Matching a page like this one never means you qualify. Each research team decides eligibility at screening.
Questions
Will I have to stop my diabetes medicine?
Some studies change or pause medicines under close supervision; many add a study treatment on top of your current care. Never change medicines on your own; the study team and your doctor decide this together.